5-Amino-1MQWhat the studies show

The interest started with a 2014 paper in Nature. Researchers used antisense oligonucleotides to switch off NNMT in the fat and liver of mice on a high-fat diet, and the mice stayed lean: they gained less weight, had smaller fat cells and used more energy, without eating less ³. That made the enzyme a drug target, and the Galveston group screened for small molecules that could block it. 5-amino-1MQ came out of that search with one useful property — it crosses cell membranes on its own — and it inhibited NNMT at roughly micromolar concentrations in the test tube and in cultured fat cells ¹.

The study that put 5-amino-1MQ on the map was published in Biochemical Pharmacology in 2018. Mice made obese on a high-fat diet were given the compound by injection under the skin for 11 days while staying on the same diet. Compared with mice given vehicle, they lost about 5% of body weight, their white fat mass and fat-cell size fell, and their plasma cholesterol dropped; food intake did not change ⁴. The treated mice's fat tissue also showed the chemical signature the researchers predicted: less of NNMT's product, 1-methylnicotinamide, and more NAD+ and S-adenosylmethionine ⁴.

Eleven days is a short study, and the losses were modest in absolute terms — a few grams in a mouse. What the paper showed is that the mechanism works in a living animal, not that the effect is large or lasting. No independent group has published a replication, and how the compound behaves in the body over longer periods — where it goes, how it is cleared — has not been described.

Old muscle regenerates poorly after injury partly because its stem cells sit dormant, and the Galveston group tested whether blocking NNMT would wake them. In 2019 they reported that an NNMT inhibitor from this series, given to 24-month-old mice after a muscle injury, increased the activation of muscle stem cells and produced larger regenerated muscle fibres than in untreated old mice ⁵. That is a single animal study and it has not been repeated by an independent laboratory.

There is no published clinical trial of 5-amino-1MQ in people, for weight or for anything else. The human evidence on NNMT is observational: higher expression of the enzyme in the fat tissue of people with insulin resistance, and higher blood levels of its product ². Those are associations, and nothing in them says what blocking the enzyme would do in a person. The compound is not an approved drug anywhere.

One caution is built into the mechanism itself. NNMT is also how the body clears surplus nicotinamide, and what happens when that route is blocked for months in a human liver has not been studied. The mouse work ran for days, in one laboratory, with no long-term follow-up.